Results in Chemistry · 2022 · 23 citations · 54 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryMolecular PharmacologyLigand BindingLigand-based DesignMolecular DockingOncology PharmacologyProtein-ligand DockingTyrosine Kinase InhibitorsAnticancer ActivityBinding Free EnergyEgfr InhibitionEpidermal Growth Factor Receptor InhibitionMolecular Docking AnalysisMolecular Simulation AnalysisProtein-ligand Binding Free EnergyProtein-ligand Binding Free Energy Calculations
Epidermal growth factor receptor tyrosine kinase domain (EGFR-TKD) plays a crucial role in the onset and progression of different types of cancers. The existing EGFR-TKD inhibitors have many adverse side effects, which make them unsuitable to be used as cancer therapeutics. This study aims to design novel molecular scaffolds that inhibit the EGFR-TKD with minimal side effects and further evaluate their suitability as an anti-cancer drug molecule using in vitro cell models. The binding energy of thiazolo-[2,3-b] quinazolinone derivatives against EGFR-TKD was determined using molecular docking and compared with positive control erlotinib (AQ44). Molecular docking demonstrated that higher bindings were exhibited by 1FTQ to 5 FTQ and the binding score ranged from -8.13 ± 0.0115 to -8.89 ± 0.0173 kcal/mol, which is higher than erlotinib -7.54 ± 0.1411 and noscapine -7.31± 0.5211 kcal/mol. Further, molecular dynamic simulations were performed to assess the stability of newly designed derivatives with EGFR-TKD. The stability of synthesized ligands was computed from the root mean square deviations. The enhanced free energy binding ΔGbind displayed by 4FTQ and 5FTQ was found to be -89.246 and -89.811 kJ/mol, which was comparable to the ΔGbind exhibited by erlotinib -130.595 kJ/mol, and a drastic decrease in free energy binding was shown by noscapine -25.98 kJ/mol. Moreover, the other synthetic congeners (1FTQ, 2FTQ, 3FTQ, 4FTQ, and 5FTQ) exhibited comparable free binding energy (ΔGbind), calculated by the MM-PBSA method. The anti-cancer activity of the compounds was assessed experimentally by a cell proliferation assay using Hep-G2 and MCF-7 cancer cell lines. Compound 3FTQ demonstrated the most potent anti-cancer activity against Hep-G2 with an IC50 value of 13.8 μM while compound 2FTQ showed promising anticancer activity against MCF-7 with an IC50 value of 21.1 μM. This study concluded that the compounds 1FTQ to 5FTQ may possess promising inhibitory activity against EGFR-TKD.
54
NIH Image to ImageJ: 25 years of image analysis
Caroline A Schneider, Wayne Rasband, Kevin W. Eliceiri · Nature Methods · 2012 · 65.2K citations
LINCS: A linear constraint solver for molecular simulations
Berk Hess, Henk Bekker, Herman J. C. Berendsen et al. · Journal of Computational Chemistry · 1997 · 17.1K citations
Natural Sciences, Chemistry, Physics +14
Open Babel: An open chemical toolbox
Noel M. O’Boyle, Michael Banck, Craig A. James et al. · Journal of Cheminformatics · 2011 · 11.1K citations · Full text